Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

API Manufacturing: SOP for Management of IPC Outliers and Investigations – V 2.0

Posted on By

API Manufacturing: SOP for Management of IPC Outliers and Investigations – V 2.0

Standard Operating Procedure for Management of IPC Outliers and Investigations in API Manufacturing

Department API Manufacturing
SOP No. SOP/API/092/2025
Supersedes SOP/API/092/2022
Page No. Page 1 of 10
Issue Date 13/04/2025
Effective Date 15/04/2025
Review Date 13/04/2026

1. Purpose

To define the procedure for the identification, documentation, investigation, and resolution of Out of Trend (OOT) or Out of Specification (OOS) in-process control (IPC) results in API manufacturing, ensuring consistent process control and compliance with GMP.

2. Scope

This SOP applies to all IPC tests conducted during API production where the results fall outside established limits or exhibit abnormal trends

requiring investigation and corrective action.

3. Responsibilities

  • Production Operator: Immediately report any IPC result outside specification or expected range.
  • QC Analyst: Verify the result, initiate rechecking if justified, and inform QA for deviation handling.
  • QA Officer: Lead the investigation, determine root cause, and initiate CAPA as needed.
See also  API Manufacturing: SOP for Emergency Handling in Solvent Area - V 2.0

4. Accountability

The Production Head and QC Head are accountable for accurate reporting and timely investigation of IPC outliers. QA Head is responsible for closure of investigation and ensuring regulatory compliance.

5. Procedure

5.1 Identification of Outlier Results

  1. Any IPC result deviating from the target or defined specification limit must be flagged immediately.
  2. Examples include unexpected pH, LOD, yield, color, assay, or TLC/HPLC profiles.
  3. Use predefined limits from MFR or IPC test methods for comparison.

5.2 Initial Assessment

  1. Production and QC jointly assess potential assignable causes:
    • Instrument error
    • Sampling error
    • Calculation mistake
    • Human error
  2. If assignable cause is identified and justifiable, recheck may be allowed with QA approval.

5.3 Repeat Testing Criteria

  1. Repeat analysis must be justified and documented in IPC Outlier Investigation Form (Annexure-1).
  2. Only two re-tests permitted; original result must not be discarded or replaced without investigation closure.
  3. If retest confirms the outlier, initiate deviation and stop further processing if needed.
See also  API Manufacturing: SOP for Batch Record Documentation and Verification - V 2.0

5.4 Investigation and Documentation

  1. QA initiates formal investigation using deviation or non-conformance form.
  2. Include details such as:
    • Batch No., IPC test performed, date/time
    • Initial and retest results
    • Possible causes, corrective action, preventive action (CAPA)
  3. Root cause analysis may involve tools like 5-Why or Fishbone diagram.

5.5 Disposition and Closure

  1. QA Head reviews investigation report and decides on batch status: Reprocess, reject, or proceed.
  2. Final decision and justification to be recorded in the batch record.
  3. Investigation should be closed within 10 working days.

6. Abbreviations

  • IPC: In-Process Control
  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • QC: Quality Control
  • OOT: Out of Trend
  • OOS: Out of Specification
  • CAPA: Corrective and Preventive Action
See also  API Manufacturing: SOP for Handling Electrostatic Charge during Milling - V 2.0

7. Documents

  1. IPC Outlier Investigation Form (Annexure-1)
  2. Batch Manufacturing Record
  3. CAPA Register / Logbook

8. References

  • ICH Q7 – GMP for APIs
  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211 – US FDA GMP

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: IPC Outlier Investigation Form

Date Batch No. Test Performed Observed Result Limit Re-Test Results Root Cause CAPA Status
13/04/2025 API-20250413 pH 2.1 3.0–5.0 2.1, 2.2 Incorrect neutralization Training & SOP update Closed

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP Release Regulatory Compliance QA Head
13/04/2025 2.0 Defined retesting limits and deviation timelines Audit Improvement QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: Elixir Department: SOP for Dispensing of Preservatives for Elixirs – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version